



Improving life from the inside out

Radius
300 Technology Square, 5th Floor
Cambridge, MA 02139
(617) 551-4700
(617) 551-4701 Fax
www.radiuspharm.com

FOR IMMEDIATE RELEASE

Contact:

Nick Harvey
Chief Financial Officer
(617) 551-4704

Radius Raises Additional \$15 Million, Increasing Second Private Equity Financing Round to \$82.5 Million

CAMBRIDGE, Mass., November 20, 2008— Radius Health (“Radius”) announced today that it has raised an additional \$15 million to its second institutional financing round, increasing total Series C investment to \$82.5 million and the total amount raised since the company’s inception to \$106.5 million. All existing institutional investors participated in the financing, led by MPM Bio IV NVS Strategic Fund and including MPM Capital, The Wellcome Trust, HealthCare Ventures, Oxford Bioscience Partners, BB Biotech Ventures, and Scottish Widows Investment Partnership.

Radius will use the additional funding, along with existing cash resources, to support the continued advancement of the company’s clinical and preclinical development programs. Radius anticipates results from its Phase II clinical trial of BA058, a bone anabolic therapy for the treatment of osteoporosis, in the first quarter of 2009. Earlier this year, the company initiated a Phase I clinical trial of RAD1901, a novel SERM (selective estrogen receptor modulator) for the treatment of hot flashes, on which Radius expects to commence a Phase IIa study in the first quarter of 2009. In addition, the company recently announced selection of the first preclinical candidate from its SARM (selective androgen receptor modulator) discovery program for treatment of muscle loss, with an investigational new drug (IND) filing expected in the second quarter of 2009.

“We are extremely pleased with the strong continuing confidence of our investors in Radius’ progress,” said C. Richard Lyttle, PhD, President and CEO of Radius. “We are finishing 2008 in a strong position, with a broad and maturing portfolio of drug candidates for osteoporosis and women’s health, an option agreement with a major pharmaceutical company to license BA058 for late-stage development, and significant cash resources at our disposal.”

About Radius (WWW.RADIUSPHARM.COM)

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women’s health. Radius has raised \$106.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, Massachusetts.

© 2008 Radius Health Inc.

###

1 / 1